Related Experiment Video

Updated: Aug 30, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter

Martin A Giedlin1, David N Cook, Thomas W Dubensky

  • 1Cancer Research, Cerus Corporation, 2411 Stanwell Drive, Concord, CA 94520, USA.

Cancer Cell
|October 31, 2003
PubMed

Insights

New vesicular stomatitis virus (VSV) mutants show enhanced tumor cell targeting. These viruses selectively replicate in cancer cells with impaired antiviral defenses, offering potential for oncolytic cancer therapy.

Area of Science:

  • Virology
  • Cancer Biology
  • Immunology

Background:

  • Vesicular stomatitis virus (VSV) is a RNA virus with oncolytic potential.
  • Normal cells possess antiviral defenses, including interferon-beta (IFN-beta) signaling, which restrict VSV replication.
  • Tumor cells often exhibit defective antiviral responses, creating an environment permissive to viral replication.

Purpose of the Study:

  • To develop VSV mutants with enhanced selectivity for tumor cells.
  • To investigate the potential of these VSV mutants as systemic oncolytic agents for cancer treatment.

Main Methods:

  • Generation and characterization of VSV mutant strains.
  • Assessment of VSV replication and infectivity in normal versus tumor cell lines.
  • Evaluation of the antiviral response pathways in infected cells.

Main Results:

  • Selected VSV mutants demonstrated impaired ability to counteract endogenous IFN-beta signaling in normal cells.
  • These VSV mutants exhibited significantly enhanced and selective productive growth in tumor cells with defective antiviral responses.
  • The findings suggest a mechanism for improved tumor targeting by engineered VSV.

Conclusions:

  • VSV mutants unable to overcome host IFN-beta responses are selectively replicated in tumor cells.
  • These engineered VSV strains hold promise as oncolytic virotherapy agents for systemic treatment of metastatic cancers.

More Related Videos

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid07:24

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Published on: May 25, 2022

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...